



September 2024

IMPORTANT CLARIFICATION REGARDING TEGSEDI IN LATAM

PTC Therapeutics has exclusive rights from Akcea Therapeutics Inc, now Ionis Pharmaceuticals to commercialize Tegsedi (inotersen) in Latin America and certain Caribbean countries. PTC has been treating hATTR patients in Latin America for over 5 years and remains committed to the hereditary amyloidosis community in this region and the continued supply for Tegsedi (inotersen) to patients in the region.